# Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD

> **NCT04932980** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Berner Augenklinik** · enrollment: 80 (estimated)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept
- **DRUG:** Brolucizumab
- **PROCEDURE:** early treat and extend (T&E)

## Key facts

- **NCT ID:** NCT04932980
- **Lead sponsor:** Berner Augenklinik
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-09
- **Primary completion:** 2027-06
- **Final completion:** 2028-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- medignition AG

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04932980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04932980, "Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04932980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*